Orchestra BioMed (OBIO) Form 4: 15,000 RSUs Granted to Director

Rhea-AI Filing Summary

Orchestra BioMed Holdings, Inc. (OBIO) filed a Form 4 reporting that director Chris Cleary was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the grant is recorded with a price of $0 in the filing. The RSUs are scheduled to vest on the one-year anniversary of the grant date, subject to the reporting persons continuous service through that date.

The transaction is shown as an acquisition and, after the award, Mr. Cleary beneficially owns 37,577 shares on a direct basis. The Form 4 was filed by one reporting person and was signed by an attorney-in-fact on 08/08/2025.

Positive

• Award recorded: Reporting person acquired 15,000 RSUs on 08/07/2025.
• Clear vesting terms: RSUs vest on the one-year anniversary, subject to continuous service.
• Beneficial ownership disclosed: Direct beneficial ownership increased to 37,577 shares following the grant.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine director RSU award of 15,000 units increases direct ownership to 37,577; no immediate cash paid, neutral material impact.

The Form 4 documents a standard equity grant recorded as an acquisition on 08/07/2025 for 15,000 RSUs with an indicated price of $0. Each RSU converts to one share upon vesting; these units vest on the one-year anniversary subject to continuous service. The filing shows direct beneficial ownership of 37,577 shares after the grant. This is a common compensation event and, based solely on the filing, does not present a material, market-moving change to the company's capital structure.

Corporate Governance Expert

TL;DR: Standard governance practice: time-based RSU grant to a director with one-year vesting tied to continued service.

The award is documented as a restricted stock unit grant with vesting conditional on continuous service through the one-year anniversary of the grant date. The Form 4 identifies the reporting person as a director and the filing was made by one reporting person. The record shows the transaction was executed on 08/07/2025 and the Form was signed by an attorney-in-fact on 08/08/2025. From a governance perspective, this is a routine equity compensation event that aligns director remuneration with shareholder outcomes upon vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cleary Chris

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share ("Common Stock")	08/07/2025		A		15,000(1)	A	$0	37,577	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date.

	/s/ Andrew Taylor, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did OBIO director Chris Cleary receive on 08/07/2025?

Chris Cleary was awarded 15,000 restricted stock units (RSUs), each representing a contingent right to one share of common stock.

When do the RSUs awarded to Chris Cleary vest?

The RSUs vest on the one-year anniversary of the grant date (08/07/2026), subject to continuous service through that date.

How many shares does Chris Cleary beneficially own after the grant?

Following the award, Chris Cleary beneficially owns 37,577 shares on a direct basis as reported in the Form 4.

What price is listed for the RSU grant in the Form 4?

The grant is recorded with a price of $0 in the filing.

Who filed and signed the Form 4 for this transaction?

The Form 4 was filed by one reporting person and was signed by an attorney-in-fact (Andrew Taylor) on 08/08/2025.